Mariëtte Boon

Dr. Mariëtte Boon


Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2015 in Journal of Lipid Research
Verified
Journal Article
Open access
PDF file
PKP. Padmini S. J. Khedoe
P. Padmini S. J. Khedoe
GHGeerte Hoeke
Geerte Hoeke
SKSander Kooijman
Sander Kooijman
WDWieneke Dijk
Wieneke Dijk
Jeroen BuijsJeroen Buijs
Jeroen Buijs
PRPatrick C. N. Rensen
Patrick C. N. Rensen
P. Padmini S. J. Khedoe, Geerte Hoeke, Sander Kooijman, Wieneke Dijk, Jeroen T. Buijs, Sander Kersten, Louis M. Havekes, Pieter S. Hiemstra, Jimmy F. P. Berbée, Mariëtte R. Boon, Patrick C. N. Rensen

1 March 2014 in The Lancet Diabetes & Endocrinology
Verified
Journal Article
Closed access
LBLeontine E H Bakker
Leontine E H Bakker
MBMariëtte Boon
Mariëtte Boon
RLRianne A D van der Linden
Rianne A D van der Linden
LALenka Pereira Arias-Bouda
Lenka Pereira Arias-Bouda
JKJan B van Klinken
Jan B van Klinken
PRPatrick C N Rensen
Patrick C N Rensen

1 February 2014 in Journal of Lipid Research
Verified
Journal Article
Open access
PDF file
JGJanine J. Geerling
Janine J. Geerling
MBMariëtte Boon
Mariëtte Boon
SKSander Kooijman
Sander Kooijman
EPEdwin T. Parlevliet
Edwin T. Parlevliet
LHLouis M. Havekes
Louis M. Havekes
PRPatrick C. N. Rensen
Patrick C. N. Rensen
Janine J. Geerling, Mariëtte R. Boon, Sander Kooijman, Edwin T. Parlevliet, Louis M. Havekes, Johannes A. Romijn, Illiana M. Meurs, Patrick C. N. Rensen

1 August 2011 in Cytokine & Growth Factor Reviews
Verified
Journal Article
Closed access
MBMariëtte Boon
Mariëtte Boon
GHGeertje van der Horst
Geertje van der Horst
GPGabri van der Pluijm
Gabri van der Pluijm
JTJouke T. Tamsma
Jouke T. Tamsma
JSJohannes W.A. Smit
Johannes W.A. Smit
PRPatrick C.N. Rensen
Patrick C.N. Rensen

16 September 2013 in PLOS ONE
Verified
Journal Article
Open access
PDF file
MBMariëtte Boon
Mariëtte Boon
SBSjoerd A. A. van Den Berg
Sjoerd A. A. van Den Berg
YWYanan Wang
Yanan Wang
Jan Van den BosscheJan Van den Bossche
Jan Van den Bossche
SKSofia Karkampouna
Sofia Karkampouna
PRPatrick C. N. Rensen
Patrick C. N. Rensen
Brown adipose tissue (BAT) dissipates energy stored in triglycerides as heat via the uncoupling protein UCP-1 and is a promising target to combat hyperlipidemia and obesity. BAT is densely innervated by the sympathetic nervous system, which increases BAT differentiation and activity upon cold exposure. Recently, Bone Morphogenetic Protein 7 (BMP7) was identified as an inducer of BAT differentiation. We aimed to elucidate the role of sympathetic activation in the effect of BMP7 on BAT by treating mice with BMP7 at varying ambient temperature, and assessed the therapeutic potential of BMP7 in combating obesity. High-fat diet fed lean C57Bl6/J mice were treated with BMP7 via subcutaneous osmotic minipumps for 4 weeks at 21°C or 28°C, the latter being a thermoneutral temperature in which sympathetic activation of BAT is largely diminished. At 21°C, BMP7 increased BAT weight, increased the expression of Ucp1, Cd36 and hormone-sensitive lipase in BAT, and increased total energy expenditure. BMP7 treatment markedly increased food intake without affecting physical activity. Despite that, BMP7 diminished white adipose tissue (WAT) mass, accompanied by increased expression of genes related to intracellular lipolysis in WAT. All these effects were blunted at 28°C. Additionally, BMP7 resulted in extensive ‘browning’ of WAT, as evidenced by increased expression of BAT markers and the appearance of whole clusters of brown adipocytes via immunohistochemistry, independent of environmental temperature. Treatment of diet-induced obese C57Bl6/J mice with BMP7 led to an improved metabolic phenotype, consisting of a decreased fat mass and liver lipids as well as attenuated dyslipidemia and hyperglycemia. Together, these data show that BMP7-mediated recruitment and activation of BAT only occurs at subthermoneutral temperature, and is thus likely dependent on sympathetic activation of BAT, and that BMP7 may be a promising tool to combat obesity and associated disorders.

25 August 2014 in The FASEB Journal
Verified
Journal Article
Open access
PDF file
MBMariëtte Boon
Mariëtte Boon
SKSander Kooijman
Sander Kooijman
ADAndrea D. van Dam
Andrea D. van Dam
LPLeonard R. Pelgrom
Leonard R. Pelgrom
JBJimmy F. P. Berbée
Jimmy F. P. Berbée
PRPatrick C. N. Rensen
Patrick C. N. Rensen
The endocannabinoid system is an important player in energy metabolism by regulating appetite, lipolysis, and energy expenditure. Chronic blockade of the cannabinoid 1 receptor (CB1R) leads to long‐term maintenance of weight loss and reduction of dyslipidemia in experimental and human obesity. The molecular mechanism by which CB1R blockade reverses dyslipidemia in obesity has not yet been clarified. In this study, we showed that CB1R blockade with the systemic CB1R blocker rimonabant enhanced whole‐body energy expenditure and activated brown adipose tissue (BAT), indicated by increased expression of genes involved in BAT thermogenesis and decreased lipid droplet size in BAT. This was accompanied by selectively increased triglyceride (TG) uptake by BAT and lower plasma TG levels. Interestingly, the effects on BAT activation were still present at thermoneutrality and could be recapitulated by using the strictly peripheral CB1R antagonist AM6545, indicating direct peripheral activation of BAT. Indeed, CB1R blockade directly activated T37i brown adipocytes, resulting in enhanced uncoupled respiration, most likely via enhancing cAMP/PKA signaling via the adrenergic receptor pathway. Our data indicate that selective targeting of the peripheral CB1R in BAT has therapeutic potential in attenuating dyslipidemia and obesity.—Boon, M. R., Kooijman, S., van Dam, A. D., Pelgrom, L. R., Berbée, J. F. P., Visseren, C. A. R., van Aggele, R. C., van den Hoek, A. M., Sips, H. C. M., Lombès, M., Havekes, L. M., Tamsma, J. T., Guigas, B., Meijer, O. C., Jukema, J. W., Rensen, P. C. N., Peripheral cannabinoid 1 receptor blockade activates brown adipose tissue and diminishes dyslipidemia and obesity. FASEB J. 28, 5361–5375 (2014). www.fasebj.org